Jonathan Mow
Directeur Général chez PHASEBIO PHARMACEUTICALS, INC.
Postes actifs de Jonathan Mow
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/09/2014 | - |
| Directeur Général | 01/09/2014 | - | |
| Corporate Officer/Principal | 04/12/2012 | 01/09/2014 | |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Directeur Général | 20/06/2023 | - |
Historique de carrière de Jonathan Mow
Anciens postes connus de Jonathan Mow
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2007 | - |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Fondateur | 01/01/2001 | 01/01/2006 |
| Secrétaire Général | 01/01/2001 | 01/01/2006 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/1995 | 01/01/1997 |
| Syntex Laboratories, Inc. | Corporate Officer/Principal | - | - |
| Lederle International | Corporate Officer/Principal | - | - |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Corporate Officer/Principal | - | - |
Formation de Jonathan Mow
| University of California, Berkeley | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 11 |
Opérationnelle
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectorielle
| Health Technology | 7 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
PathoGenesis Corp
PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
| Syntex Laboratories, Inc. | |
| Lederle International | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
- Bourse
- Insiders
- Jonathan Mow
- Expérience
